サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1661058

院内疾患検査市場レポート：適応症別、地域別、2025年～2033年

Hospital Acquired Disease Testing Market Report by Indication (UTI (Urinary Tract Infection), SSI (Surgical Site Infection), Pneumonia, Bloodstream Infections, MRSA (Methicillin-Resistant Staphylococcus Aureus), and Others), and Region 2025-2033

出版日
発行
IMARC
ページ情報
英文 146 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
院内疾患検査市場レポート：適応症別、地域別、2025年～2033年
出版日: 2025年02月10日
発行: IMARC
ページ情報: 英文 146 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

院内疾患検査の世界市場規模は2024年に140億米ドルに達しました。今後、IMARC Groupは、市場は2033年までに494億米ドルに達し、2025年から2033年にかけて15％の成長率（CAGR）を示すと予測しています。市場を牽引する要因はいくつかあり、高齢者人口の増加、尿路感染症（UTI）、血流感染症、肺炎などの院内感染（HAI）の有病率の増加、さまざまな外科手術を受ける人の増加などが挙げられます。

院内感染症は、病院や診療所で発症する疾患です。院内感染とは、病院内で発生する感染症や病気を意味します。特別養護老人ホーム、リハビリテーションセンター、病院、その他の臨床環境の近くでも、このような病気にかかる可能性があります。ほとんどの人は集中治療室（ICU）や救急治療室（ER）にいるときにHAIに感染します。一般的に、これらの疾患の潜伏期間は、患者が入院してから48時間から4日の間です。院内感染の主な原因は、病院内のスタッフが適切な衛生管理を行っていないことです。その他の理由としては、メンテナンスの不備、病院スタッフの自己満足、多剤耐性菌（MDRO）の増加などが挙げられます。最もよく発生する院内感染には、肺炎、一次血流感染、尿路感染などがあります。多くの場合、これらの院内感染症は患者自身のマイクロバイオームに起因することもあることがわかっています。感染症は、特に外科手術の後などに、皮膚の保護層が脅威となりうるものと接触し、感染を引き起こすことで発生します。

市場動向：

人口の増加とヘルスケア・インフラの近代化により、世界中でヘルスケア施設の数が大幅に増加しています。その結果、HAIの発生率が上昇し、院内感染検査の需要を牽引しています。さらに、高度な技術と科学的革新により、マイクロアレイ、ポリメラーゼ連鎖反応（PCR）、リアルタイム・ロケーション・システム（RTLS）、固相ハイブリダイゼーションなど、HAIの予防、診断、モニタリングのためのさまざまな技術が市場で利用できるようになった。RTLSのような技術は、患者とスタッフの両方におけるHAIの蔓延を防ぐことを容易にします。患者の間でのHAIに対する意識の高まりや、HAIの発生率が高い病院を罰する規制を制定する政府の動きは、市場の成長を促進するその他の要因の一部です。

本レポートで扱う主な質問

  • 2024年の世界の院内疾患検査市場の市場規模は？
  • 2025-2033年の世界の院内疾患検査市場成長率は？
  • 世界の院内疾患検査市場促進要因は何か？
  • 世界の院内疾患検査市場の主要産業動向は？
  • 世界の院内疾患検査市場に対するCOVID-19の影響は？
  • 世界の院内疾患検査市場の適応症別内訳は？
  • 世界の院内疾患検査市場の主要地域は？
  • 世界の院内疾患検査市場における主要企業／プレーヤーは？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 世界の院内疾患検査市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場内訳：適応症別
  • 市場内訳：地域別
  • 市場予測
  • SWOT分析
    • 概要
    • 強み
    • 弱み
    • 機会
    • 脅威
  • バリューチェーン分析
  • ポーターのファイブフォース分析
    • 概要
    • 買い手の交渉力
    • 供給企業の交渉力
    • 競合の程度
    • 新規参入業者の脅威
    • 代替品の脅威
  • 価格分析

第6章 市場内訳：適応症別

  • UTI（尿路感染症）
    • 市場動向
    • 市場予測
  • SSI（手術部位感染）
    • 市場動向
    • 市場予測
  • 肺炎
    • 市場動向
    • 市場予測
  • 血流感染症
    • 市場動向
    • 市場予測
  • MRSA（メチシリン耐性黄色ブドウ球菌）
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第7章 市場内訳：地域別

  • 北米
    • 市場動向
    • 市場予測
  • 欧州
    • 市場動向
    • 市場予測
  • アジア太平洋地域
    • 市場動向
    • 市場予測
  • 中東・アフリカ
    • 市場動向
    • 市場予測
  • ラテンアメリカ
    • 市場動向
    • 市場予測

第8章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Abbott Laboratories
    • Alere, Inc.
    • Becton, Dickinson and Company
    • bioMerieux SA
    • F. Hoffmann-La Roche Ltd.
    • Hologic, Inc.
    • QIAGEN
    • Siemens Healthcare
    • Diatherix Laboratories, Inc.
    • Meridian Bioscience, Inc.
    • Thermo Fisher Scientific, Inc.（Life Technologies Corporation）
    • Cepheid, Inc.
図表

List of Figures

  • Figure 1: Global: Hospital Acquired Disease Testing Market: Major Drivers and Challenges
  • Figure 2: Global: Hospital Acquired Disease Testing Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Hospital Acquired Disease Testing Market: Breakup by Indication (in %), 2024
  • Figure 4: Global: Hospital Acquired Disease Testing Market: Breakup by Region (in %), 2024
  • Figure 5: Global: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 6: Global: Hospital Acquired Disease Testing Industry: SWOT Analysis
  • Figure 7: Global: Hospital Acquired Disease Testing Industry: Value Chain Analysis
  • Figure 8: Global: Hospital Acquired Disease Testing Industry: Porter's Five Forces Analysis
  • Figure 9: Global: Hospital Acquired Disease Testing (Urinary Tract Infection) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 10: Global: Hospital Acquired Disease Testing (Urinary Tract Infection) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 11: Global: Hospital Acquired Disease Testing (Surgical Site Infection) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 12: Global: Hospital Acquired Disease Testing (Surgical Site Infection) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 13: Global: Hospital Acquired Disease Testing (Pneumonia) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 14: Global: Hospital Acquired Disease Testing (Pneumonia) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 15: Global: Hospital Acquired Disease Testing (Bloodstream Infections) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 16: Global: Hospital Acquired Disease Testing (Bloodstream Infections) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 17: Global: Hospital Acquired Disease Testing (Methicillin-Resistant Staphylococcus Aureus) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 18: Global: Hospital Acquired Disease Testing (Methicillin-Resistant Staphylococcus Aureus) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 19: Global: Hospital Acquired Disease Testing (Other Indications) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 20: Global: Hospital Acquired Disease Testing (Other Indications) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 21: North America: Hospital Acquired Disease Testing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 22: North America: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 23: Europe: Hospital Acquired Disease Testing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 24: Europe: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 25: Asia Pacific: Hospital Acquired Disease Testing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 26: Asia Pacific: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 27: Middle East and Africa: Hospital Acquired Disease Testing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 28: Middle East and Africa: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 29: Latin America: Hospital Acquired Disease Testing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 30: Latin America: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Million USD), 2025-2033

List of Tables

  • Table 1: Global: Hospital Acquired Disease Testing Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Hospital Acquired Disease Testing Market Forecast: Breakup by Indication (in Million USD), 2025-2033
  • Table 3: Global: Hospital Acquired Disease Testing Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 4: Global: Hospital Acquired Disease Testing Market: Competitive Structure
  • Table 5: Global: Hospital Acquired Disease Testing Market: Key Players
目次
Product Code: SR112025A1128

The global hospital acquired disease testing market size reached USD 14.0 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 49.4 Billion by 2033, exhibiting a growth rate (CAGR) of 15% during 2025-2033. There are several factors that are driving the market, which include the rising geriatric population, increasing prevalence of hospital acquired infections (HAIs) like urinary tract infections (UTIs), bloodstream infections, and pneumonia, and the growing number of people undergoing different surgical procedures.

Hospital-acquired infections (HAIs) or nosocomial infections are diseases that are acquired in hospitals and medical clinics. Nosocomial means, infections or diseases originating in a hospital. A person can get such diseases even in the vicinity of a nursing home, rehabilitation center, hospital or any other clinical surroundings. Most people get HAIs when they are in intensive care units (ICUs) and emergency rooms (ERs). Generally, the incubation period of these diseases vary between 48 hours to 4 days after the individual gets admitted. A major reason behind the cause of hospital-acquired diseases is the lack of proper hygiene in the hospital settings by the internal staff. Other reasons can be below-par maintenance, complacency by the hospital staff, and a rise in multi-drug resistant organisms (MDROs). Some of the most commonly occurring nosocomial infections include pneumonia, primary bloodstream infections, urinary tract infections, etc. In many cases, it has also been found that these nosocomial infections are sometimes traced to the patient's own microbiome. It happens when the protective skin layer comes in contact with possible threats and causes infection to occur, especially after surgical operations.

Market Trends:

Catalyzed by rising population and modernization of the healthcare infrastructure, there has been a significant increase in the number of health care facilities across the globe. This has resulted in a rising incidence of HAIs, driving the demand of hospital acquired disease tests. Moreover, with advanced technologies and scientific innovations, various techniques are now available in the market for preventing, diagnosing, and monitoring HAIs such as microarrays, polymerase chain reaction (PCR), real time location systems (RTLSs), and solid phase hybridization. Techniques such as RTLS makes it easy to prevent HAIs from spreading in both patients and staff. Growing awareness of HAIs among patients and governments enacting regulations that penalize hospitals having a high incidence of HAIs are some of the other factors that are catalyzing the growth of the market.

Key Market Segmentation:

Breakup by Indication:

  • UTI (Urinary Tract Infection)
  • SSI (Surgical Site Infection)
  • Pneumonia
  • Bloodstream Infections
  • MRSA (Methicillin-Resistant Staphylococcus Aureus)
  • Others

Based on the indication, the market has been segmented into urinary tract infection, surgical site infection, pneumonia, bloodstream infections, methicillin-resistant staphylococcus aureus and others. Urinary tract infection currently represents the biggest segment.

Regional Insights:

  • North America
  • Europe
  • Asia Pacific
  • Middle East and Africa
  • Latin America
  • Region-wise, the market has been segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Competitive Landscape:

  • The competitive landscape of the market has also been examined with some of the key players being Abbott Laboratories, Alere, Inc., Becton, Dickinson and Company, bioMerieux SA, F. Hoffmann-La Roche Ltd., Hologic, Inc., QIAGEN, Siemens Healthcare, Diatherix Laboratories, Inc., Meridian Bioscience, Inc., Thermo Fisher Scientific, Inc. (Life Technologies Corporation) and Cepheid, Inc.
  • This report provides a deep insight into the global hospital-acquired disease testing market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter's five forces analysis, value chain analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the hospital-acquired disease testing market in any manner.

Key Questions Answered in This Report

  • 1.What is the market size for the global hospital acquired disease testing market 2024?
  • 2.What is the global hospital acquired disease testing market growth 2025-2033?
  • 3.What are the global hospital acquired disease testing market drivers?
  • 4.What are the key industry trends in the global hospital acquired disease testing market?
  • 5.What is the impact of COVID-19 on the global hospital acquired disease testing market?
  • 6.What is the global hospital acquired disease testing market breakup by indication?
  • 7.What are the major regions in the global hospital acquired disease testing market?
  • 8.Who are the key companies/players in the global hospital acquired disease testing market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Hospital Acquired Disease Testing Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Breakup by Indication
  • 5.5 Market Breakup by Region
  • 5.6 Market Forecast
  • 5.7 SWOT Analysis
    • 5.7.1 Overview
    • 5.7.2 Strengths
    • 5.7.3 Weaknesses
    • 5.7.4 Opportunities
    • 5.7.5 Threats
  • 5.8 Value Chain Analysis
  • 5.9 Porters Five Forces Analysis
    • 5.9.1 Overview
    • 5.9.2 Bargaining Power of Buyers
    • 5.9.3 Bargaining Power of Suppliers
    • 5.9.4 Degree of Competition
    • 5.9.5 Threat of New Entrants
    • 5.9.6 Threat of Substitutes
  • 5.10 Price Analysis

6 Market Breakup by Indication

  • 6.1 UTI (Urinary Tract Infection)
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 SSI (Surgical Site Infection)
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Pneumonia
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Bloodstream Infections
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 MRSA (Methicillin-Resistant Staphylococcus Aureus)
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Others
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast

7 Market Breakup by Region

  • 7.1 North America
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Europe
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Asia Pacific
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Middle East and Africa
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Latin America
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Competitive Landscape

  • 8.1 Market Structure
  • 8.2 Key Players
  • 8.3 Profiles of Key Players
    • 8.3.1 Abbott Laboratories
    • 8.3.2 Alere, Inc.
    • 8.3.3 Becton, Dickinson and Company
    • 8.3.4 bioMerieux SA
    • 8.3.5 F. Hoffmann-La Roche Ltd.
    • 8.3.6 Hologic, Inc.
    • 8.3.7 QIAGEN
    • 8.3.8 Siemens Healthcare
    • 8.3.9 Diatherix Laboratories, Inc.
    • 8.3.10 Meridian Bioscience, Inc.
    • 8.3.11 Thermo Fisher Scientific, Inc. (Life Technologies Corporation)
    • 8.3.12 Cepheid, Inc.